UPDATE: Deutsche Bank Raises PT to $92 on Alexion

Deutsche Bank reiterates its Buy rating on Alexion ALXN and boosts its price target by $14 to $92 on a pipeline that should make for revenue growth in 2012. Deutsche Bank says, "Alexion investing in pipeline - New TP $92 on STEC HUS & asfotase alfa. - 2012 is shaping up to be a year of revenue growth & increased R&D investment for Alexion. We see Soliris revenue growing as aHUS launch progresses. We see fruits of investment beginning to emerge in late 2013/2014 with launch of 1) Soliris in STEC HUS & kidney transplant & 2) asfotase alfa (Enobia acquisition) for hypophosphatasia (HPP). We are now including STEC HUS & asfotase alfa opportunities, which increases our TP to $92." ALXN closed at $80.41 a share on Thursday.